PTEN and prostate carcinoma: In this study, we characterized the antitumor activity of apalutamide in well-established, genetically engineered mouse models of Pten-deficient prostate cancer, modeled to reflect castration-naïve prostate cancer (CNPC) and CRPC in early cancer and late-stage disease settings.